Marinobufagenin levels in preeclamptic patients: A preliminary report

American Journal of Perinatology

Volumn 28, Issue 7, 2011, Pages 509-514

  Agunanne, Enoch ^a   Horvat, Darijana ^a   Harrison, Recherael ^a   Uddin, M Nasir ^a   Jones, Richard ^a   Kuehl, Thomas J ^a   Ghanem, Daad Abi ^b   Berghman, Luc R ^b   Lai, Xinzhong ^b   Li, Jing ^b   Romo, Daniel ^b   Puschett, Jules B ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

cardiotonic steroids; marinobufagenin; Preeclampsia; pregnancy hypertension

Indexed keywords

BETA LACTOGLOBULIN; BUFOGENIN; CREATININE; MARINOBUFAGENIN;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHEMIFLUORESCENT ENZYME LINKED IMMUNOSORBENT ASSAY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HEART RATE; HUMAN; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE;

ADULT; BUFANOLIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY;

EID: 79960835117     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0031-1272965     Document Type: Article

References (24)

1. Pridjian G, Puschett J B. Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002 57 598-618 (Pubitemid 34977665)
2. Pridjian G, Puschett J B. Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv 2002 57 619-640 (Pubitemid 34977666)
3. Ness R B., Roberts J M. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996 175 1365-1370 (Pubitemid 26399006)
4. Puschett J B., Agunanne E, Uddin M N. Marinobufagenin, resibufogenin and preeclampsia. Biochim Biophys Acta. 2010 2 1246-1253
5. Maynard S E., Min J Y., Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003 111 649-658 (Pubitemid 36278583)
6. Hypertensive disorders in pregnancy. Chapter 34. In: Cunningham F G. Gant N F. Leveno K G. Gilstrap L C. Hauth J C. Wenstrom K D. eds. Williams Textbook of Obstetrics, 22nd ed. New York McGraw-Hill 2005 762-808
7. Vu H V., Ianosi-Irimie M R., Pridjian C A. et al. Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005 25 520-528 (Pubitemid 41433898)
8. Abi-Ghanem D, Berghman L R., Romo D et al. A chemifluorescent immunoassay for the determination of marinobufagenin in body fluids. J Immunoassay Immunochem 2011 32 31-46
9. Averina I V., Tapilskaya N I., Reznik V A. et al. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia. Cell Mol Biol (Noisy-le-grand) 2006 52 19-23 (Pubitemid 46799700)
10. Lopatin D A., Ailamazian E K., Dmitrieva R I. et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999 17 1179-1187 (Pubitemid 29389566)
11. Gonick H C., Ding Y, Vaziri N D., Bagrov A Y., Fedorova O V. Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens 1998 20 617-627 (Pubitemid 28319534)
12. Bagrov A Y., Fedorova O V., Dmitrieva R I., French A W., Anderson D E. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res 1996 31 296-305 (Pubitemid 26090901)
13. Bagrov A Y., Fedorova O V., Austin-Lane J L., Dmitrieva R I., Anderson D E. Endogenous marinobufagenin-like immunoreactive factor and Na+, K+ATPase inhibition during voluntary hypoventilation. Hypertension 1995 26 781-788
14. Songu-Mize E, Bealer S L., Caldwell R W. Effect of DOCA-salt treatment duration and anteroventral third ventricle lesions on a plasma-borne sodium pump inhibitor in rats. J Hypertens 1987 5 461-467
15. Deray G, Pernollet M G., Devynck M A. et al. Plasma digitalislike activity in essential hypertension or end-stage renal disease. Hypertension 1986 8 632-638 (Pubitemid 16066768)
16. Sagnella G A., Jones J C., Shore A C., Markandu N D., MacGregor G A. Evidence for increased levels of a circulating ouabainlike factor in essential hypertension. Hypertension 1986 8 433-437 (Pubitemid 16051111)
17. Whitley G S., Cartwright J E. Trophoblast-mediated spiral artery remodelling: a role for apoptosis. J Anat 2009 215 21-26
18. LaMarca H L., Morris C A., Pettit G R., Nagowa T, Puschett J B. Marinobufagenin impairs first trimester cytotrophoblast differentiation. Placenta 2006 27 984-988 (Pubitemid 44204032)
19. Uddin M N., Horvat D, Glaser S S. et al. Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells. Placenta 2008 29 266-273
20. Norwitz E R., Schust D J., Fisher S J. Implantation and the survival of early pregnancy. N Engl J Med 2001 345 1400-1408
21. Pijnenborg R, Dixon G, Robertson W B., Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980 1 3-19 (Pubitemid 11240946)
22. Vu H, Ianosi-Irimie M, Danchuk S et al. Resibufogenin corrects hypertension in a rat model of human preeclampsia. Exp Biol Med (Maywood) 2006 231 215-220 (Pubitemid 43213459)
23. Agunanne E, Horvat D, Uddin M N., Puschett J B. The treatment of preeclampsia in a rat model employing Digibind. Am J Perinatol 2010 27 299-305
24. Horvat D, Severson J, Uddin M N., Mitchell B, Puschett J B. Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome. Hypertens Pregnancy 2010 29 1 1-9